ClinicalTrials.gg
Active, not recruitingNCT05463952Updated Nov 13, 2024Results posted

A Study to Learn About the Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (BC)

A Phase 1 interventional study of vepdegestrant in Breast Neoplasms, sponsored by Pfizer. Active, not recruiting at 3 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-11-13.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing vepdegestrant in Breast Neoplasms — 1 open to participants now, 6 under way, 2 of them phase 3. vepdegestrant · Breast Neoplasms.

Enrollment
12th of 12
6 · median 48
Started
2022
with 1 other
Phase 1
3 of 12
none open now
Registered
3rd of 12
by date
Lead sponsor
8 of 12
Pfizer

Among the 12 studies testing vepdegestrant in Breast Neoplasms, this one is the 12th largest by enrollment, is one of 2 that started in 2022, is one of 3 in phase 1, and was the 3rd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

1 of the 12 studies testing vepdegestrant in Breast Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vepdegestrant

vepdegestrant: first FDA approval 2026 (VEPPANU). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing vepdegestrant in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this clinical trial is to learn about the safety, tolerability, Pharmacokinetics (PK), and preliminary efficacy of ARV-471 as monotherapy in Japanese participants with ER+/HER2- locally advanced or metastatic breast cancer (mBC).

03

Conditions studied

  • Breast Neoplasms

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants (women and men) at least 20 years of age at the time of signing the .
  2. Histological or cytological diagnosis of ER+/- advanced breast cancer that is , recurrent, or locally advanced unresectable breast cancer.
  3. Participants who are resistant to standard therapy or for which no standard therapy is available or have received.
  4. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the Infromed Consent Document (ICD) and in this protocol.
  5. (ECOG) Performance Status 0 or 1.
  6. Adequate Bone Marrow or Coagulation Function.
  7. Adequate Renal Function, defined as an estimated ≥60 mL/min as calculated using the method standard for the institution.
  8. Adequate Liver Function.
  9. Participants with must meet all the specified conditions.
  10. Resolution of acute effects of any prior therapy to either baseline severity or version 5.0 Grade ≤1.

Exclusion criteria

Exclusion Criteria:

  1. Participants with any other active within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix, Bowen's disease.
  2. Participants sustaining major surgery defined as a complex procedure performed under regional or general anesthesia with a recovery period of at least 4 weeks prior to study enrollment.
  3. Known or suspected or severe allergy to active ingredient/ of ARV-471.
  4. Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  5. Radiation therapy within 4 weeks of first dose of study drug or prior irradiation to >25% of the bone marrow. Palliative radiation for the alleviation of pain due to bone will be allowed during the study.
  6. Concurrent administration of medications, foods or herbal supplements that are strong inhibitors or inducers of and drugs with a known risk of causing Torsade de Pointes or prolongation. Prior use of strong CYP3A inhibitors and drugs with a known risk of causing Torsade de Pointes or QT interval prolongation must be stopped 7 days before enrollment and strong CYP3A inducers must be stopped 14 days before enrollment.
  7. Prior treatment with ARV-471.
  8. Systemic anticancer therapy chemotherapy or endocrine therapy within 14 days prior to study entry (6 weeks for mitomycin C or nitrosoureas). If the last immediate anticancer treatment contained an antibody-based agent(s) (approved or ), then an interval of 28 days or 5 half-lives (whichever is shorter) of the agent(s) prior to receiving the study intervention treatment is required.
  9. Participants who have initiated therapy with bone-modifying agents (bisphosphonates, denosumab, or similar) within 14 days of enrollment.
  10. Previous high-dose chemotherapy requiring stem cell rescue.
  11. Participation in other studies involving investigational drug(s) within 4 weeks prior to study entry. A participant may be eligible even if they are in the follow-up phase of an investigational study as long as they haven't received treatment in the study for 5 half lives of the agents.
  12. Serum pregnancy test (for females of ) positive at screening and/or a breastfeeding participant.
  13. Participants with active, uncontrolled bacterial, fungal, or viral infection, including (but not limited to) Virus (HBV), Virus (HCV), and known (HIV) or Acquired Immunodeficiency Syndrome (AIDS)-related illness.
  14. Baseline standard 12 lead (ECG) that demonstrates abnormalities that may affect participant safety or interpretation of study results.
  15. Any of the following in the previous 12 months: myocardial infarction, long QT syndrome, Torsade de Pointes, clinically important atrial or ventricular arrhythmias, serious conduction system abnormalities, unstable angina, coronary/peripheral artery bypass graft, symptomatic CHF, class III or IV, cerebrovascular accident, , symptomatic pulmonary embolism, and/or other clinical significant episode of thrombo-embolic disease. Ongoing cardiac dysrhythmias of Grade ≥2, atrial fibrillation of any grade . If a participant has a cardiac rhythm device/pacemaker placed and QTcF >470 ms, the participant may be considered eligible. Participants with cardiac rhythm device/pacemaker must be discussed in detail with the sponsor to judge eligibility.
  16. History of symptomatic cardiac valve disease.
  17. Active inflammatory gastrointestinal disease, chronic diarrhea, known diverticular disease or previous gastric resection or lap band surgery.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    vepdegestrant

    Daily oral dosages of vepdegestrant

    Drug: vepdegestrant

Interventions

  • ARV-471 will be administered orally QD with food, in continuous dosing over 28-day cycles.

    Also known as: ARV-471, PF-07850327

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose Limiting Toxicity (DLTs) During First Treatment Cycle

    DLT was defined as any adverse event (AE) or abnormal laboratory value which were related to ARV-471 and assessed as unrelated to disease, disease progression, intercurrent illness or concomitant medications/therapies occurring during the first 28 days of treatment that met at least 1 of the study specified criteria.

    Time frame: Cycle 1 (28 days)

Secondary outcomes

  1. Number of Participants With AEs and Serious AEs (SAEs)- All Causalities and Treatment Related

    An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Relatedness was judged by investigator. SAE was an AE resulted in any of the following outcomes: death, inpatient hospitalization or prolongation of existing hospitalization; was life-threatening experience (immediate risk of dying); resulted in persistent or significant disability/incapacity; congenital anomaly, a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic.

    Time frame: Day 1 of study treatment up to 35 days after last dose of study treatment (approximately 1.5 years)

  2. Number of Participants With Laboratory Hematology Results by Maximum National Cancer Institute Common Terminology Criteria (NCI-CTCAE) Grade

    The following hematology parameters were assessed: hemoglobin, platelets, white blood cell (WBC), absolute neutrophils, absolute lymphocytes, absolute monocytes, absolute eosinophils and absolute basophils. Laboratory abnormality events were graded according to NCI CTCAE v 5.0 (grade 0=no change from normal or reference range, grade 1=mild, grade 2= moderate, grade 3= severe, grade 4= life-threatening and grade 5= death related).

    Time frame: During study treatment, approximately 1.5 years

  3. Number of Participants With Laboratory Chemistry Results by Maximum NCI-CTCAE Grade

    The following chemistry parameters were assessed: aspartate transaminase (AST), alkaline phosphatase (ALP), sodium, potassium, magnesium, chloride, total calcium, total bilirubin, blood urea nitrogen (BUN) or urea, creatinine, uric acid, glucose (non-fasted), albumin, phosphorus or phosphate, creatinine kinase (CK), amylase and lipase. Laboratory abnormality events were graded according to NCI CTCAE v 5.0 (grade 0=no change from normal or reference range, grade 1=mild, grade 2= moderate, grade 3= severe, grade 4= life-threatening and grade 5= death related).

    Time frame: During study treatment, approximately 1.5 years

  4. Area Under the Plasma Concentration-Time Curve From Time Zero to Time Tau (AUCtau) of ARV 471 and ARV-473

    Time frame: Through the end of the study treatment (approximately 1.5 years)

  5. Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of ARV-471 and ARV-473

    Time frame: Through the end of the study treatment (approximately 1.5 years)

  6. Maximum Observed Plasma Concentration (Cmax) of ARV-471 and ARV-473

    Time frame: Through the end of the study treatment (approximately 1.5 years)

  7. Time to Reach Maximum Concentration (Tmax) of ARV-471 and ARV-473

    Time frame: Through the end of the study treatment (approximately 1.5 years)

  8. Terminal Elimination Half-Life (t1/2) of ARV-471 and ARV-473

    Time frame: Through the end of the study treatment (approximately 1.5 years)

  9. Metabolite Ratio for Cmax (MRCmax)

    Time frame: Through the end of the study treatment (approximately 1.5 years)

  10. Metabolite Ratio for AUCtau (MRAUCtau)

    Time frame: Through the end of the study treatment (approximately 1.5 years)

  11. Lowest Concentration Observed During the Dosing Interval (Cmin) of ARV-471 and ARV-473

    Time frame: Through the end of the study treatment (approximately 1.5 years)

  12. Pre-dose Plasma Concentration (Ctrough) of ARV-471 and ARV-473

    Time frame: Through the end of the study treatment (approximately 1.5 years)

  13. Apparent Total Clearance (CL/F) of ARV-471

    Time frame: Through the end of the study treatment (approximately 1.5 years)

  14. Apparent Volume of Distribution (Vz/F) of ARV-471

    Time frame: Through the end of the study treatment (approximately 1.5 years)

  15. Effective Half-Life Based on Accumulation Ratio (t½Eff) of ARV-471 and ARV-473

    Time frame: Through the end of the study treatment (approximately 1.5 years)

  16. Accumulation Ratio (Rac) Based on AUC of ARV-471 and ARV-473

    Time frame: Through the end of the study treatment (approximately 1.5 years)

  17. Objective Response Rate (ORR)

    ORR is defined as the percentage of participants with best overall response (BOR) of complete response (CR) and partial response (PR) as per Response Evaluation Criteria in Solid Tumours (RECIST version \[v\] 1.1). BOR: best response was recorded from start of study treatment until disease progression or death due to any cause. CR: complete disappearance of all target lesions with exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis less than \[\<\]10 millimeter \[mm\]). PR: greater than or equal to (\>=) 30 percent (%) decrease under baseline of sum of diameters of all targets measurable lesions. Short axis was used in sum for target nodes, while longest diameter was used in sum for all other target lesions. All target lesions were assessed.

    Time frame: From start of study treatment until disease progression or death due to any cause (approximately 1.5 years)

  18. Clinical Benefit Response (CBR)

    CBR is defined as the percentage of participants with BOR of CR, PR and stable disease (SD) of 24 weeks duration or longer. As per RECIST v1.1. SD: Does not qualify for CR, PR or Progression. All target lesions must be assessed. Stable could follow PR only in the rare case that the sum increased by \<20% from the nadir, but enough that a previously documented 30% decrease no longer held. CR: complete disappearance of all target lesions and non-target disease, with exception of nodal disease. All nodes, both target and non-target, must decrease to normal short axis \<10 mm). No new lesions. PR: \>= 30% decrease under baseline of sum of diameters of all targets measurable lesions. Short diameter was used in sum for target nodes, while longest diameter was used in sum for all other target lesions.

    Time frame: From start of study treatment until disease progression or death due to any cause (approximately 1.5 years)

  19. Progression Free Survival (PFS)

    PFS was defined as the time from first dose of study treatment (ie, start date) to the date of progression of disease (PD) or death due to any cause, whichever occurred first. PFS data was censored on the date of the last adequate tumor assessment for participants without an event (PD or death), for participants who started new anti-cancer treatment prior to an event, or for participants with an event after two or more missing tumor assessments. PD as per RECIST v1.1 for target lesions was defined as 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum is observed during therapy), with a minimum absolute increase of 5 mm. For non-target lesions- PD was defined as unequivocal progression of pre-existing lesions. Analysis was performed using Kaplan-Meier method.

    Time frame: From start of study treatment until disease progression or death due to any cause or censoring date (approximately 1.5 years)

  20. Duration of Response (DOR)

    Duration of response was defined as the time from the first documentation of objective tumor response to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first in participants with confirmed objective response (CR or PR). CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. Analysis was performed using Kaplan-Meier method.

    Time frame: From the first documentation of objective tumor response to the first documentation of objective tumor progression or to death due to any cause (approximately 1.5 years)

07

Results

Posted Sep 23, 2024

Participant flow

Japanese participants with estrogen receptor (ER+) or human epidermal growth factor receptor 2 (HER-2) locally advanced or metastatic breast cancer (mBC) were treated with ARV-471 (PF-07850327) as monotherapy. A total of 6 participants were enrolled.

Treatment
Participant flow — Treatment
MilestoneARV-471 200 mg
Started6
Completed0
Not completed6
Withdrew: Progressive disease4
Withdrew: Ongoing2
Follow-up
Participant flow — Follow-up
MilestoneARV-471 200 mg
Started4
Completed4
Not completed0

Outcome measures

PrimaryNumber of Participants With Dose Limiting Toxicity (DLTs) During First Treatment Cycle

DLT was defined as any adverse event (AE) or abnormal laboratory value which were related to ARV-471 and assessed as unrelated to disease, disease progression, intercurrent illness or concomitant medications/therapies occurring during the first 28 days of treatment that met at least 1 of the study specified criteria.

Time frame:
Cycle 1 (28 days)
Reported as:
Count of participants · Participants
Number of Participants With Dose Limiting Toxicity (DLTs) During First Treatment Cycle
ParticipantsARV-471 200 mg
Number of Participants With Dose Limiting Toxicity (DLTs) During First Treatment Cycle0
SecondaryNumber of Participants With AEs and Serious AEs (SAEs)- All Causalities and Treatment Related

An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Relatedness was judged by investigator. SAE was an AE resulted in any of the following outcomes: death, inpatient hospitalization or prolongation of existing hospitalization; was life-threatening experience (immediate risk of dying); resulted in persistent or significant disability/incapacity; congenital anomaly, a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic.

Time frame:
Day 1 of study treatment up to 35 days after last dose of study treatment (approximately 1.5 years)

Results for this outcome have not been posted.

SecondaryNumber of Participants With Laboratory Hematology Results by Maximum National Cancer Institute Common Terminology Criteria (NCI-CTCAE) Grade

The following hematology parameters were assessed: hemoglobin, platelets, white blood cell (WBC), absolute neutrophils, absolute lymphocytes, absolute monocytes, absolute eosinophils and absolute basophils. Laboratory abnormality events were graded according to NCI CTCAE v 5.0 (grade 0=no change from normal or reference range, grade 1=mild, grade 2= moderate, grade 3= severe, grade 4= life-threatening and grade 5= death related).

Time frame:
During study treatment, approximately 1.5 years

Results for this outcome have not been posted.

SecondaryNumber of Participants With Laboratory Chemistry Results by Maximum NCI-CTCAE Grade

The following chemistry parameters were assessed: aspartate transaminase (AST), alkaline phosphatase (ALP), sodium, potassium, magnesium, chloride, total calcium, total bilirubin, blood urea nitrogen (BUN) or urea, creatinine, uric acid, glucose (non-fasted), albumin, phosphorus or phosphate, creatinine kinase (CK), amylase and lipase. Laboratory abnormality events were graded according to NCI CTCAE v 5.0 (grade 0=no change from normal or reference range, grade 1=mild, grade 2= moderate, grade 3= severe, grade 4= life-threatening and grade 5= death related).

Time frame:
During study treatment, approximately 1.5 years

Results for this outcome have not been posted.

SecondaryArea Under the Plasma Concentration-Time Curve From Time Zero to Time Tau (AUCtau) of ARV 471 and ARV-473
Time frame:
Through the end of the study treatment (approximately 1.5 years)

Results for this outcome have not been posted.

SecondaryArea Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of ARV-471 and ARV-473
Time frame:
Through the end of the study treatment (approximately 1.5 years)

Results for this outcome have not been posted.

SecondaryMaximum Observed Plasma Concentration (Cmax) of ARV-471 and ARV-473
Time frame:
Through the end of the study treatment (approximately 1.5 years)

Results for this outcome have not been posted.

SecondaryTime to Reach Maximum Concentration (Tmax) of ARV-471 and ARV-473
Time frame:
Through the end of the study treatment (approximately 1.5 years)

Results for this outcome have not been posted.

SecondaryTerminal Elimination Half-Life (t1/2) of ARV-471 and ARV-473
Time frame:
Through the end of the study treatment (approximately 1.5 years)

Results for this outcome have not been posted.

SecondaryMetabolite Ratio for Cmax (MRCmax)
Time frame:
Through the end of the study treatment (approximately 1.5 years)

Results for this outcome have not been posted.

SecondaryMetabolite Ratio for AUCtau (MRAUCtau)
Time frame:
Through the end of the study treatment (approximately 1.5 years)

Results for this outcome have not been posted.

SecondaryLowest Concentration Observed During the Dosing Interval (Cmin) of ARV-471 and ARV-473
Time frame:
Through the end of the study treatment (approximately 1.5 years)

Results for this outcome have not been posted.

SecondaryPre-dose Plasma Concentration (Ctrough) of ARV-471 and ARV-473
Time frame:
Through the end of the study treatment (approximately 1.5 years)

Results for this outcome have not been posted.

SecondaryApparent Total Clearance (CL/F) of ARV-471
Time frame:
Through the end of the study treatment (approximately 1.5 years)

Results for this outcome have not been posted.

SecondaryApparent Volume of Distribution (Vz/F) of ARV-471
Time frame:
Through the end of the study treatment (approximately 1.5 years)

Results for this outcome have not been posted.

SecondaryEffective Half-Life Based on Accumulation Ratio (t½Eff) of ARV-471 and ARV-473
Time frame:
Through the end of the study treatment (approximately 1.5 years)

Results for this outcome have not been posted.

SecondaryAccumulation Ratio (Rac) Based on AUC of ARV-471 and ARV-473
Time frame:
Through the end of the study treatment (approximately 1.5 years)

Results for this outcome have not been posted.

SecondaryObjective Response Rate (ORR)

ORR is defined as the percentage of participants with best overall response (BOR) of complete response (CR) and partial response (PR) as per Response Evaluation Criteria in Solid Tumours (RECIST version \[v\] 1.1). BOR: best response was recorded from start of study treatment until disease progression or death due to any cause. CR: complete disappearance of all target lesions with exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis less than \[\<\]10 millimeter \[mm\]). PR: greater than or equal to (\>=) 30 percent (%) decrease under baseline of sum of diameters of all targets measurable lesions. Short axis was used in sum for target nodes, while longest diameter was used in sum for all other target lesions. All target lesions were assessed.

Time frame:
From start of study treatment until disease progression or death due to any cause (approximately 1.5 years)

Results for this outcome have not been posted.

SecondaryClinical Benefit Response (CBR)

CBR is defined as the percentage of participants with BOR of CR, PR and stable disease (SD) of 24 weeks duration or longer. As per RECIST v1.1. SD: Does not qualify for CR, PR or Progression. All target lesions must be assessed. Stable could follow PR only in the rare case that the sum increased by \<20% from the nadir, but enough that a previously documented 30% decrease no longer held. CR: complete disappearance of all target lesions and non-target disease, with exception of nodal disease. All nodes, both target and non-target, must decrease to normal short axis \<10 mm). No new lesions. PR: \>= 30% decrease under baseline of sum of diameters of all targets measurable lesions. Short diameter was used in sum for target nodes, while longest diameter was used in sum for all other target lesions.

Time frame:
From start of study treatment until disease progression or death due to any cause (approximately 1.5 years)

Results for this outcome have not been posted.

SecondaryProgression Free Survival (PFS)

PFS was defined as the time from first dose of study treatment (ie, start date) to the date of progression of disease (PD) or death due to any cause, whichever occurred first. PFS data was censored on the date of the last adequate tumor assessment for participants without an event (PD or death), for participants who started new anti-cancer treatment prior to an event, or for participants with an event after two or more missing tumor assessments. PD as per RECIST v1.1 for target lesions was defined as 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum is observed during therapy), with a minimum absolute increase of 5 mm. For non-target lesions- PD was defined as unequivocal progression of pre-existing lesions. Analysis was performed using Kaplan-Meier method.

Time frame:
From start of study treatment until disease progression or death due to any cause or censoring date (approximately 1.5 years)

Results for this outcome have not been posted.

SecondaryDuration of Response (DOR)

Duration of response was defined as the time from the first documentation of objective tumor response to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first in participants with confirmed objective response (CR or PR). CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. Analysis was performed using Kaplan-Meier method.

Time frame:
From the first documentation of objective tumor response to the first documentation of objective tumor progression or to death due to any cause (approximately 1.5 years)

Results for this outcome have not been posted.

Adverse events

Collected over Day 1 of study treatment up to 35 days last dose of study treatment (maximum up to 33 weeks as maximum treatment exposure was 28 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ARV-471 200 mg0/6 (0%)0/6 (0%)4/6 (66.7%)
Most frequent other events
Showing 10 of 15
Most frequent other events
EventARV-471 200 mg
AnaemiaBlood and lymphatic system disorders1/6
Abdominal discomfortGastrointestinal disorders1/6
Abdominal painGastrointestinal disorders1/6
ConstipationGastrointestinal disorders1/6
NauseaGastrointestinal disorders1/6
PyrexiaGeneral disorders1/6
Seasonal allergyImmune system disorders1/6
COVID-19Infections and infestations1/6
Alanine aminotransferase increasedInvestigations1/6
Aspartate aminotransferase increasedInvestigations1/6

Baseline characteristics

Full analysis set included all participants who have been assigned to ARV-471.

Age, Continuous
Age, Continuous(Years)ARV-471 200 mg
Mean56.0 ± 6.10
Sex: Female, Male
Sex: Female, Male(Participants)ARV-471 200 mg
Female6
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ARV-471 200 mg
Hispanic or Latino0
Not Hispanic or Latino6
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ARV-471 200 mg
American Indian or Alaska Native0
Asian6
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
08

Study locations

3 sites
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in May 2023, 8 months.

Results were first posted in Sep 2024, 1 year 4 months after primary completion.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 8 months is below that.

Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2022
First posted
Jul 19, 2022
StartActual
Aug 16, 2022
Primary completionActual
May 4, 2023
CompletionEst.
Mar 31, 2025
Results first posted
Sep 23, 2024
Last update
Nov 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05463952
Lead sponsor
Pfizer
Collaborators
Arvinas Estrogen Receptor, Inc.
Responsible party
Sponsor
First posted
Jul 19, 2022
Start date
Aug 16, 2022
Primary completion
May 4, 2023
Completion
Mar 31, 2025 (estimated)
Results posted
Sep 23, 2024
Last update
Nov 13, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vepdegestrant

Start the discussion